Navigation Links
AACR & IASLC to host molecular origins of lung cancer conference
Date:12/15/2011

What:

The second AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine will bring together scientists to share the latest findings in the diagnosis, treatment and prevention of the nation's leading cause of cancer and cancer mortality.

The conference, scheduled for Jan. 8-11, 2012, in San Diego, is jointly sponsored by the American Association for Cancer Research and the International Association for the Study of Lung Cancer.

The conference will feature a series of groundbreaking oral presentations and hundreds of abstracts including:

  • prevention of tobacco damage using antiestrogens;
  • the role of tumor suppressor genes in small cell lung cancer;
  • a phase 2 study of sorafenib in patients with stage IV disease;
  • new tools to measure circulating tumor cells;
  • new data on microRNA and KRAS mutations

When:

Jan. 8-11, 2012

Where: San Diego Marriott Hotel & Marina San Diego, Calif.


'/>"/>
Contact: Natalie Poole
Natalie.Poole@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related biology news :

1. AVS 55th International Symposium & Exhibition, Oct. 19-24
2. Brown University and Women & Infants Hospital expand national childrens study to Bristol County
3. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
4. Columbia to award 2008 Horwitz Prize to Arthur Horwich & Ulrich Hartl for cellular protein folding
5. Singapore opens Fusionopolis, its second major R&D hub in 5 years
6. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
7. Texas A&M anthropologist discovers long-lost primate in Indonesia
8. Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics
9. Ancestral genome of present-day African great apes & humans had burst of DNA sequence duplication
10. NTU seals global partnerships on environmental sciences R&D
11. UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: